New triple attack on rare melanoma shows promise in early trial

NCT ID NCT07236528

Not yet recruiting Disease control Sponsor: The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This phase 2 trial tests a combination of two drugs (carilizumab and apatinib) plus radiation therapy as a first treatment for advanced mucosal melanoma, a rare and aggressive skin cancer. The study will enroll 30 adults who have not had prior systemic therapy. Researchers will measure how long the cancer stays under control and monitor side effects.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Carilizumab (immunotherapy), Apatinib mesylate (targeted drug), and radiotherapy
What this could lead to: If it works, this could offer a new first-line treatment option for advanced mucosal melanoma, potentially improving how long the cancer is kept under control.
What could go wrong: This is a small, early-phase trial (30 people) with no control group, so results may not be definitive. The combination of three treatments may cause significant side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MUCOSAL MELANOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

mucosal melanoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

MUCOSAL MELANOMA

More trials for these conditions

Other studies related to the condition(s) this trial covers.